Filtered By:
Condition: Kidney Transplantation
Procedure: Heart Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 142 results found since Jan 2013.

Stimulator of interferon genes (STING): Key therapeutic targets in ischemia/reperfusion injury
Biomed Pharmacother. 2023 Sep 10;167:115458. doi: 10.1016/j.biopha.2023.115458. Online ahead of print.ABSTRACTThe Stimulator of Interferon Genes (STING) is predominantly expressed in immune cells, including macrophages, natural killer cells, dendritic cells, and T cells, functioning as a pattern recognition receptor. STING activation upon detecting cytosolic DNA released from damaged cells initiates downstream pathways, leading to the production of inflammatory cytokines such as IFNs, IL-6, and TNF-α. Dysregulated STING activation has been implicated in inflammatory and metabolic diseases. Ischemia/reperfusion injury (I/R...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 12, 2023 Category: Drugs & Pharmacology Authors: Juan Lv Xuanxuan Zhu Chunlei Xing Yuhong Chen Huihui Bian Heng Yin Xiaofeng Gu Li Su Source Type: research

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
CONCLUSION: Globally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.PMID:37493856 | DOI:10.1007/s12325-023-02608-9
Source: Adv Data - July 26, 2023 Category: Epidemiology Authors: Vivekanand Jha Saeed M G Al-Ghamdi Guisen Li Mai-Szu Wu Panagiotis Stafylas Lise Retat Joshua Card-Gowers Salvatore Barone Claudia Cabrera Juan Jose Garcia Sanchez Source Type: research

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.PMID:37466151 | DOI:10.1002/14651858.CD007751.pub3
Source: Cochrane Database of Systematic Reviews - July 19, 2023 Category: General Medicine Authors: Tess E Cooper Claris Teng David J Tunnicliffe Brydee A Cashmore Giovanni Fm Strippoli Source Type: research

Outcomes of Combined Heart-Kidney Transplantation in Older Recipients
CONCLUSION: Combined HKT is increasing in older recipients, and advanced age ≥65 should not preclude HKT.PMID:37396466 | PMC:PMC10314816 | DOI:10.1155/2023/4528828
Source: Cardiology Research and Practice - July 3, 2023 Category: Cardiology Authors: Curry Sherard Vineeth Sama Jennie H Kwon Khaled Shorbaji Lauren V Huckaby Brett A Welch Chakradhari Inampudi Ryan J Tedford Arman Kilic Source Type: research

Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure
ConclusionsThe use of milrinone compared with dobutamine in patients with ADHF-CS is associated with lower 30  day mortality and improved haemodynamics. These findings warrant further study in future randomized controlled trials.
Source: ESC Heart Failure - June 16, 2023 Category: Cardiology Authors: Eduard Rodenas ‐Alesina, Fernando Luis Scolari, Vicki N. Wang, Darshan H. Brahmbhatt, Vesna Mihajlovic, Nicole L. Fung, Madison Otsuki, Filio Billia, Christopher B. Overgaard, Adriana Luk Tags: Original Article Source Type: research

Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage. Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news